Dr. Paul Goss is the Research Director of the Breast Program at MGH, Co-Director of the DFHCC and Director Avon Center of Excellence. Dr. Goss' responsibilities include assisting and guiding the internal and National and International clinical and translational breast cancer research studies. He also leads large practice changing clinical trials in early stage breast cancer and in breast cancer prevention. Three areas are currently encompassed within these trials: optimizing endocrine therapy in treatment and prevention; application of anti-Her2 therapies in early stage disease and; studies of bone metabolism in early stage cancer therapies and most recently the role of rank ligand inhibition in the prevention of breast cancer recurrence and prevention of new primary disease. Translational areas of focus include: bone metabolism; tumor signatures; pharmacogenomics of toxicities and outcomes; mammographic density; quality of life; cost effectiveness. Dr. Goss leads a new International Program which focuses on: clinical trials; tissue repositories from clinical trials, intended for translational research studies; on-line data repository and statistical analyses; minorities, ethnicity and access to care; education. Dr. Goss also leads an active exchange program of international trainees and a growing global telemedicine forum.